 DUBLIN, Sept. 13, 2021 PRNewswire -- Alkermes plc Nasdaq: ALKS today announced two poster presentations related to nemvaleukin alfa nemvaleukin, the companys novel, investigational, engineered interleukin-2 IL-2 variant immunotherapy, at the 2021 European Society for Medical Oncology ESMO Virtual Congress, taking place Sept. 